[{"orgOrder":0,"company":"Recordati","sponsor":"ARS Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ITALY","productType":"Hormone","year":"2023","type":"Acquisition","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Recordati \/ ARS Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Recordati \/ ARS Pharmaceuticals"},{"orgOrder":0,"company":"Recordati","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"ITALY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Silodosin","moa":"Alpha-1a adrenergic receptor","graph1":"Urology","graph2":"Phase IV","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Recordati \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Recordati \/ Undisclosed"},{"orgOrder":0,"company":"Recordati","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"ITALY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Fexapotide triflutate","moa":"Apoptosis||peptides: peptides with prostate cancer indications","graph1":"Urology","graph2":"Phase III","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Recordati \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Recordati \/ Undisclosed"},{"orgOrder":0,"company":"Recordati","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2024","type":"Acquisition","leadProduct":"Sutimlimab","moa":"Complement C1s","graph1":"Hematology","graph2":"Approved FDF","graph3":"Recordati","amount2":1.0800000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":1.0800000000000001,"dosageForm":"Infusion","sponsorNew":"Recordati \/ Recordati","highestDevelopmentStatusID":"15","companyTruncated":"Recordati \/ Recordati"},{"orgOrder":0,"company":"Recordati","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Phase II","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Recordati \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recordati \/ Undisclosed"},{"orgOrder":0,"company":"Recordati","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Aldosterone synthase (CYP11B2)||Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Recordati \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Recordati \/ Undisclosed"},{"orgOrder":0,"company":"Recordati","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recordati \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Recordati \/ Undisclosed"},{"orgOrder":0,"company":"Recordati","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recordati \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Recordati \/ Undisclosed"},{"orgOrder":0,"company":"Recordati","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recordati \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Recordati \/ Undisclosed"},{"orgOrder":0,"company":"Recordati","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recordati \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Recordati \/ Undisclosed"},{"orgOrder":0,"company":"Recordati","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Cytochrome P450 11B1","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recordati \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Recordati \/ Undisclosed"},{"orgOrder":0,"company":"Recordati","sponsor":"Amarin","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Recordati","amount2":0.17999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.17999999999999999,"dosageForm":"Capsule","sponsorNew":"Recordati \/ Recordati","highestDevelopmentStatusID":"15","companyTruncated":"Recordati \/ Recordati"},{"orgOrder":0,"company":"Recordati","sponsor":"Eusa Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Acquisition","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Recordati","amount2":0.84999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.84999999999999998,"dosageForm":"Infusion","sponsorNew":"Recordati \/ Recordati","highestDevelopmentStatusID":"15","companyTruncated":"Recordati \/ Recordati"},{"orgOrder":0,"company":"Recordati","sponsor":"Recordati","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Phase II","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recordati \/ Recordati","highestDevelopmentStatusID":"8","companyTruncated":"Recordati \/ Recordati"},{"orgOrder":0,"company":"Recordati","sponsor":"Tolmar","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ITALY","productType":"Peptide, Unconjugated","year":"2021","type":"Licensing Agreement","leadProduct":"Leuprolide Acetate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Recordati","amount2":0.17000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"Injection","sponsorNew":"Recordati \/ Tolmar","highestDevelopmentStatusID":"15","companyTruncated":"Recordati \/ Tolmar"},{"orgOrder":0,"company":"Recordati","sponsor":"Apices Soluciones | Asociacion Colaboracion Cochrane Iberoamericana","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"ITALY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Soybean Extract","moa":"Immune","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Recordati \/ Apices Soluciones | Asociacion Colaboracion Cochrane Iberoamericana","highestDevelopmentStatusID":"11","companyTruncated":"Recordati \/ Apices Soluciones | Asociacion Colaboracion Cochrane Iberoamericana"},{"orgOrder":0,"company":"Recordati","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"ITALY","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Siltuximab","moa":"Interleukin-6","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recordati \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recordati \/ Undisclosed"},{"orgOrder":0,"company":"Recordati","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Siltuximab","moa":"Interleukin-6","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recordati \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Recordati \/ Syneos Health"},{"orgOrder":0,"company":"Recordati","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Siltuximab","moa":"Interleukin-6","graph1":"Oncology","graph2":"Phase II","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Recordati \/ Recordati","highestDevelopmentStatusID":"8","companyTruncated":"Recordati \/ Recordati"},{"orgOrder":0,"company":"Recordati","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ITALY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Methadone","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recordati \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Recordati \/ Undisclosed"},{"orgOrder":0,"company":"Recordati","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Pasireotide","moa":"Somatostatin receptor 5","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recordati \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Recordati \/ Undisclosed"},{"orgOrder":0,"company":"Recordati","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Pasireotide","moa":"Somatostatin receptor 5","graph1":"Endocrinology","graph2":"Phase II","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recordati \/ Recordati","highestDevelopmentStatusID":"8","companyTruncated":"Recordati \/ Recordati"},{"orgOrder":0,"company":"Recordati","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Pasireotide Diaspartate","moa":"Somatostatin receptor 5 | Somatostatin receptor 3 | Somatostatin receptor 2 | Somatostatin receptor 1","graph1":"Endocrinology","graph2":"Phase II","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recordati \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recordati \/ Undisclosed"},{"orgOrder":0,"company":"Recordati","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"ITALY","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Rec 0\/0438","moa":"Undisclosed","graph1":"Urology","graph2":"Phase I\/ Phase II","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recordati \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Recordati \/ Undisclosed"},{"orgOrder":0,"company":"Recordati","sponsor":"Trial Form Support S.L. | Apices Soluciones","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ITALY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Sodium Picosulfate","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase III","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recordati \/ Trial Form Support S.L. | Apices Soluciones","highestDevelopmentStatusID":"10","companyTruncated":"Recordati \/ Trial Form Support S.L. | Apices Soluciones"},{"orgOrder":0,"company":"Recordati","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ITALY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lercanidipine","moa":"Voltage-gated L-type calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recordati \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recordati \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals by Recordati
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
